Expertise in
5
conditions

Dr. Susan Melin

Internal Medicine
Office
301 Medical Ctr Blvd Fl 3, 
Winston Salem, NC 
Expertise in
5
conditions
Office
301 Medical Ctr Blvd Fl 3, 
Winston Salem, NC 

Overview

Susan Melin is an Internal Medicine provider in Winston Salem, North Carolina. Dr. Melin is highly rated in 5 conditions, according to our data. Her top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, Inflammatory Breast Cancer, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 16 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Internal Medicine

Licenses

Internal Medicine in NC

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Office
301 Medical Ctr Blvd Fl 3, Winston Salem, NC 27103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
Enrollment Status: Completed
Publish Date: September 30, 2025
Intervention Type: Drug
Study Drugs: tucatinib, trastuzumab deruxtecan
Study Phase: Phase 2
Increasing Adherence to Adjuvant Hormonal Therapy Among Breast Cancer Patients: Phase 2 - Pilot Test of Intervention for Feasibility
Increasing Adherence to Adjuvant Hormonal Therapy Among Breast Cancer Patients: Phase 2 - Pilot Test of Intervention for Feasibility
Enrollment Status: Completed
Publish Date: June 29, 2025
Intervention Type: Other, Behavioral
Study Phase: Not Applicable
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
View 5 Less Clinical Trials

16 Total Publications

Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer.
Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer.
Journal: Clinical breast cancer
Published: August 29, 2023
Similar Doctors
Expertise in
13
conditions
Dr. Alain Bertoni
Internal Medicine
Expertise in
13
conditions
Dr. Alain Bertoni
Internal Medicine

Office

1 S Hawthorne Rd, 
Winston Salem, NC 
 (1.2 miles away)
336-716-2011
Languages Spoken:
English
See accepted insurances

Alain Bertoni is a primary care provider, practicing in Internal Medicine in Winston Salem, North Carolina. Dr. Bertoni is highly rated in 13 conditions, according to our data. His top areas of expertise are Atherosclerosis, Type 2 Diabetes (T2D), Heart Failure, and Maturity Onset Diabetes of the Young.

Expertise in
5
conditions
Dr. Jamy Ard
Internal Medicine
Expertise in
5
conditions
Dr. Jamy Ard
Internal Medicine

Atrium Health Wake Forest Baptist Travel Medicine-Country Club

4614 Country Club Rd, 
Winston Salem, NC 
 (3.6 miles away)
336-713-0708
Languages Spoken:
English
See accepted insurances

Jamy Ard is a primary care provider, practicing in Internal Medicine in Winston Salem, North Carolina. Dr. Ard is highly rated in 5 conditions, according to our data. His top areas of expertise are Obesity, Obesity in Children, Type 2 Diabetes (T2D), Metabolic Syndrome, and Sleeve Gastrectomy.

Expertise in
39
conditions
Dr. Paul Savage
Internal Medicine
Expertise in
39
conditions
Dr. Paul Savage
Internal Medicine

Office

301 Medical Ctr Blvd Fl 3, 
Winston Salem, NC 
 (3.6 miles away)
336-713-5440
Languages Spoken:
English
See accepted insurances

Paul Savage is an Internal Medicine provider in Winston Salem, North Carolina. Dr. Savage is highly rated in 39 conditions, according to our data. His top areas of expertise are Bone Tumor, Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Bone Marrow Aspiration, and Endoscopy.

Frequently Asked Questions about Dr. Susan Melin

How do I make an appointment with Dr. Susan Melin?

You can book an appointment with Dr. Susan Melin by calling their office at 336-713-5440. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Susan Melin a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Susan Melin is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Susan Melin specialize in?

While Dr. Susan Melin is a Internal Medicine, they have specific expertise in Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Susan Melin participate in research or clinical trials?

Yes. Dr. Susan Melin has published 16 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Susan Melin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Susan Melin accept my insurance?

Dr. Susan Melin accepts most major insurance plans, including Aetna and AmeriHealth. We recommend calling the office directly at 336-713-5440 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Melin's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile